Announcements Trials
Browse Landscape

Phase

Phase 2 35Phase 1 16Phase 1/2 5Phase 3 4Phase NA 1Phase EARLY_PHASE1 1

Status

Recruiting 2Completed 2Suspended 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 2Other solid neoplasm 1Genitourinary 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Solid Tumor 1Prostatic Neoplasms, Castration-Resistant 1Pancreatic Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × zimberelimab × Clear all
NCT05419479 2026-02-24

Switch Maintenance in Pancreatic

Dana-Farber Cancer Institute

Phase 1/2 Suspended
46 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06238921 2025-12-05

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Recruiting
31 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04660812 2025-10-20

ARC-9

Arcus Biosciences, Inc.

Phase 1/2 Completed
227 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT04381832 2025-07-22

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Arcus Biosciences, Inc.

Phase 1/2 Completed
173 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT05909436 2023-06-18

Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors

Guangzhou Gloria Biosciences Co., Ltd.

Phase 1/2 Recruiting
107 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡